SCHEMBL5135989

SCHEMBL5135989

CCCCN(Cc1ccc(OC)c(OC)c1OC)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
POLB P06746 1/20 0.39
BCHE P06276 5/20 0.38
KDM4E B2RXH2 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
RAB9A P51151 1/20 0.37
C5AR1 P21730 1/20 0.36
PKM P14618 1/20 0.36
GAA P10253 2/20 0.35
TP53 P04637 1/20 0.35
HDAC1 Q13547 1/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070121 0.95 SMN1; SMN2 (0.41) SMN1; SMN2POLBBCHEKDM4ERAB9A
SCHEMBL5137367 0.94 KDM4E (0.37) SMN1; SMN2BCHEKDM4ECYP1A2CYP2D6
SCHEMBL5137007 0.92 DRD2 (0.38) SMN1; SMN2POLBBCHEKDM4EC5AR1
SCHEMBL5070081 0.92 SMN1; SMN2 (0.36) SMN1; SMN2BCHEKDM4ECYP1A2CYP2D6
SCHEMBL5138090 0.89 TP53 (0.40) SMN1; SMN2BCHEKDM4EC5AR1GAA
SCHEMBL5137330 0.89 BCHE (0.43) BCHEC5AR1KMT2AMEN1
SCHEMBL5134803 0.89 BCHE (0.43) BCHEC5AR1
SCHEMBL5134688 0.88 TP53 (0.39) SMN1; SMN2BCHEKDM4EC5AR1GAA
SCHEMBL5136649 0.87 LMNA (0.43) SMN1; SMN2KDM4EC5AR1GAATP53
SCHEMBL5136445 0.86 DRD2 (0.38) SMN1; SMN2BCHEKDM4EC5AR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed